First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL Meeting Abstract

  

Authors:	Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; Abdel-Wahab, O.; Tallman, M. S.
Abstract Title:	First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
Meeting Title:	63rd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	138
Issue:	Suppl. 1
Meeting Dates:	2021 Dec 11-14
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2021-11-23
Language:	English
ACCESSION:	WOS:000736398800043
DOI:	10.1182/blood-2021-151074
PROVIDER:	wos
Notes:	Meeting Abstract: 43 -- Hybrid meeting, also took place online -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/198905